1 Abcrnethy DR. Pharmacologic and pharmacoki-netic profile of mibcfradil, a T-and L-typer calci-um channel antagonist. Am J Cardiol, 1997; 80(4B):4C
2 Mehrke G. Zong X, Flocherzi V, et al. The Ca2+-channel blocker Ro 40-5967 blocks differently T-typer and L-typer Ca2+-channels. J Pharmacol Exp Ther, I994;27l: 1483
3 Files TD. Introduction of mibcfradil. Am J Cardiol, 1997; 80(4B): IC
4 Oparil S, Bernink P, Bursztyn M, et al. Antihy-periensive effects of mibefradil in the treatment of mildtomoderate systemic hypertension. Am J Cardiol. 1997;80(4B):27C
5 Massie BM, Bernink P, Brusztyn M, et al. Mibcfradil in the treatment of systemic hyperten-sion:comparative studies with other calcium antagonists. Am J Cardiol, 1997;52:314
6 Schmitt R, Kleinbloesem C, Belz G,et al. Hemo-dynamic and humoral effects of the novel calcium antagonist Ro 40-5967 in patients with hyperten-sion. Clin Pharmacol thery 1992; 52:314
7 Bakx ALM, Van der Wall EE, Braun S, et al. Effects of the new calcium antagonist mibefradil (Ro 40-5967) on exercise duration in patients with chronic stable angina pectoris:a multicenter,place-bocontroliec study. Am Heart J, 1995; 130:748
8 Alpert JS, Bakx ALM, Braun S, et al. Antianginal and anti-ischemic effects of mibefradil in the treatment of patients with chronic stable angina pectoris. Am J Cardiol, 1997;80(4B):20C
9 Schneeweiss A, Kobrin I, Charlon V, et al. Adding the new calcium antagonist mibcrfradil to patients with receiving long-term (3-blocker therapy resuks in improved antianginal and antiischcmic efficacy. Am heart J, 1998;135:272
10 DaviesGJ, Tzivoni D, Kobrin I, et al.Mibefradi in the ireatmem of chronic stable angina pectoris: comparative studies with other calcium antago-nists. Am J Cardiol. 1997;80(4B):34C
11 Mulder P, Richard V, Compagnon P, et al. In-creased survival after long-term Ireatmem with mibefradil, a selective T-channel calcium antago-nist, in heart failure. J Am Coll Cardiol, 1997;27: 416
12 Rousseau MF, Hayashita W, van Eyll C,et al. Hemodynamic and cardiac effects of the selective T-type and L-type calcium channel blocker, mibefradil in patients with varying degrees of left ventricular systolic dys-function. J Am Coll Cardi-ol, 1996; 28:972
13 Kobrin I, Charlon V, Lindberg E,et al. Safety of mibefradil, a new once-a-day, selective Y-typc cal-cium channel antagonist. Am J Cardiol, 1997; 80 (4B):40C |
